The Experts below are selected from a list of 305178 Experts worldwide ranked by ideXlab platform
José L. Cohen - One of the best experts on this subject based on the ideXlab platform.
-
Regulatory T cells in graft-versus-Host Disease
Springer Seminars in Immunopathology, 2006Co-Authors: Benoit L Salomon, Muriel Sudres, José L. CohenAbstract:Alloreactive T cells present in a bone marrow transplant are responsible for graft-vs-Host Disease, but their depletion is associated with impaired engraftment, immunosuppression, and loss of the graft-vs-leukemia effect. The subpopulation of CD4^+CD25^+ immunoregulatory T cells was first identified based on its crucial role in the control of autoimmune processes, but they also play a role in alloreactive responses. Moreover, these cells could be used to develop innovative strategies in the field of transplantation and particularly to prevent graft-vs-Host Disease. Indeed, high numbers of CD4^+CD25^+ immunoregulatory T cells can modulate graft-vs-Host Disease if administered at the same time as allogeneic hematopoietic stem cell transplantation in mice. This review discusses various important issues regarding the possible use of CD4^+CD25^+ immunoregulatory T cells to modulate alloreactivity in hematopoietic stem cell transplantation.
Benoit L Salomon - One of the best experts on this subject based on the ideXlab platform.
-
Regulatory T cells in graft-versus-Host Disease
Springer Seminars in Immunopathology, 2006Co-Authors: Benoit L Salomon, Muriel Sudres, José L. CohenAbstract:Alloreactive T cells present in a bone marrow transplant are responsible for graft-vs-Host Disease, but their depletion is associated with impaired engraftment, immunosuppression, and loss of the graft-vs-leukemia effect. The subpopulation of CD4^+CD25^+ immunoregulatory T cells was first identified based on its crucial role in the control of autoimmune processes, but they also play a role in alloreactive responses. Moreover, these cells could be used to develop innovative strategies in the field of transplantation and particularly to prevent graft-vs-Host Disease. Indeed, high numbers of CD4^+CD25^+ immunoregulatory T cells can modulate graft-vs-Host Disease if administered at the same time as allogeneic hematopoietic stem cell transplantation in mice. This review discusses various important issues regarding the possible use of CD4^+CD25^+ immunoregulatory T cells to modulate alloreactivity in hematopoietic stem cell transplantation.
Muriel Sudres - One of the best experts on this subject based on the ideXlab platform.
-
Regulatory T cells in graft-versus-Host Disease
Springer Seminars in Immunopathology, 2006Co-Authors: Benoit L Salomon, Muriel Sudres, José L. CohenAbstract:Alloreactive T cells present in a bone marrow transplant are responsible for graft-vs-Host Disease, but their depletion is associated with impaired engraftment, immunosuppression, and loss of the graft-vs-leukemia effect. The subpopulation of CD4^+CD25^+ immunoregulatory T cells was first identified based on its crucial role in the control of autoimmune processes, but they also play a role in alloreactive responses. Moreover, these cells could be used to develop innovative strategies in the field of transplantation and particularly to prevent graft-vs-Host Disease. Indeed, high numbers of CD4^+CD25^+ immunoregulatory T cells can modulate graft-vs-Host Disease if administered at the same time as allogeneic hematopoietic stem cell transplantation in mice. This review discusses various important issues regarding the possible use of CD4^+CD25^+ immunoregulatory T cells to modulate alloreactivity in hematopoietic stem cell transplantation.
Georgia Boyce Vogelsang - One of the best experts on this subject based on the ideXlab platform.
-
overlap subtype of chronic graft versus Host Disease is associated with an adverse prognosis functional impairment and inferior patient reported outcomes a chronic graft versus Host Disease consortium study
Haematologica, 2012Co-Authors: Joseph Pidala, Steven Z. Pavletic, Barry E. Storer, Xiaoyu Chai, Georgia Boyce Vogelsang, Corey Cutler, Madan Jagasia, Daniel J Weisdorf, Paul J Martin, Jeanne PalmerAbstract:Background The National Institutes of Health Consensus Conference proposed the term “overlap” graft- versus -Host Disease to describe the situation when both acute and chronic graft- versus -Host Disease are present. Design and Methods We examined whether the overlap subtype of graft- versus -Host Disease was associated with a different prognosis, functional limitations, or patient-reported outcomes compared to “classic” chronic graft- versus -Host Disease without any acute features. Results Prospective data were collected from 427 patients from nine centers. Patients were classified as having overlap (n=352) or classic chronic (n=75) graft- versus -Host Disease based on reported organ involvement. Overlap cases had a significantly shorter median time from transplantation to cohort enrollment ( P =0.01), were more likely to be incident cases ( P <0.001), and had a lower platelet count at onset of the graft- versus -Host Disease ( P <0.001). Patients with overlap graft- versus -Host Disease had significantly greater functional impairment measured by a 2-minute walk test, higher symptom burden and lower Human Activity Profile scores. Quality of life was similar, except patients with overlap graft- versus -Host Disease had worse social functioning, assessed by the Short Form-36. Multivariable analysis utilizing time-varying covariates demonstrated that the overlap subtype of graft- versus -Host Disease was associated with worse overall survival (HR 2.1, 95% CI 1.1–4.7; P =0.03) and higher non-relapse mortality (HR 2.8, 95% CI 1.2–8.3; P =0.02) than classic chronic graft- versus -Host Disease. Conclusions These findings suggest that the presence of acute features in patients with chronic graft- versus -Host Disease is a marker of adverse prognosis, greater functional impairment, and higher symptom burden.
-
Overlap subtype of chronic graft-versus-Host Disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study
Haematologica, 2011Co-Authors: Joseph Pidala, Steven Z. Pavletic, Barry E. Storer, Xiaoyu Chai, Georgia Boyce Vogelsang, Corey Cutler, Madan Jagasia, Daniel J Weisdorf, Paul Martin, Jeanne PalmerAbstract:Background The National Institutes of Health Consensus Conference proposed the term “overlap” graft- versus -Host Disease to describe the situation when both acute and chronic graft- versus -Host Disease are present. Design and Methods We examined whether the overlap subtype of graft- versus -Host Disease was associated with a different prognosis, functional limitations, or patient-reported outcomes compared to “classic” chronic graft- versus -Host Disease without any acute features. Results Prospective data were collected from 427 patients from nine centers. Patients were classified as having overlap (n=352) or classic chronic (n=75) graft- versus -Host Disease based on reported organ involvement. Overlap cases had a significantly shorter median time from transplantation to cohort enrollment ( P =0.01), were more likely to be incident cases ( P
-
Sensitivity of changes in chronic graft- versus -Host Disease activity to changes in patient-reported quality of life: results from the Chronic Graft- versus -Host Disease Consortium
Haematologica, 2011Co-Authors: Joseph Pidala, Steven Z. Pavletic, Xiaoyu Chai, Georgia Boyce Vogelsang, Corey Cutler, Brenda F. Kurland, Daniel J Weisdorf, Navneet S MajhailAbstract:Background The 2005 National Institute of Health Chronic Graft- versus -Host Disease Consensus Conference recommended collection of patient-reported outcomes in clinical trials on chronic graft- versus -Host Disease. We assessed whether changes in chronic graft- versus -Host Disease severity, determined using National Institute of Health criteria, clinicians’ assessment or patients’ self-evaluation, correlated with patient-reported quality of life as measured by the Short Form-36 and Functional Assessment of Cancer Therapy – Bone Marrow Transplant (FACT-BMT) instruments. Design and Methods Three-hundred and thirty-six adult patients (median age 52 years; range, 19 – 79) with chronic graft- versus -Host Disease from six transplant centers contributed baseline and follow-up data (from 936 visits overall). Results While the majority of the patients had stable chronic graft- versus -Host Disease, improvement or worsening was noted in approximately 40% of follow-up visits. Multivariable analysis demonstrated no association between change in chronic graft- versus -Host Disease severity evaluated by National Institute of Health criteria and change in quality of life, while clinician-reported changes in severity were associated with changes in some quality of life measures. Patient-reported changes in the severity of chronic graft- versus -Host Disease were associated with changes in all quality of life measures. Comparison of the Short Form-36 and the FACT-BMT suggested that the data collected in the Functional Assessment of Cancer Therapy – General (FACT-G) core survey are sufficient without the need for the Short Form-36 or the FACT–BMT subscale. Conclusions We conclude that serial National Institute of Health and clinician-reported chronic graft- versus -Host Disease severity assessments cannot substitute for patient-reported outcomes in clinical trials. Collection of just the FACT-G instead of the Short Form-36 and the full FACT-BMT will decrease respondent burden without compromising quality of life assessment.
-
Chronic Graft-Versus-Host Disease
Current Pharmaceutical Design, 2008Co-Authors: Javier Bolaños-meade, Georgia Boyce VogelsangAbstract:Chronic graft-versus-Host Disease is the most common late, non-relapse complication of transplantation yet it is also one of the least studied. It is the primary cause of morbidity and mortality of long-term survivors ofallogeneic bone marrow transplants. Like acute graft-versus-Host Disease, it does have a strong antitumor effect. The recent National Institutes of Health sponsored Chronic Graft-versus-Host Disease Consensus Conference has proposed new criteria for diagnosis and staging, pathology, biomarkers, response and supportive care. New understanding of the pathophysiology of chronic graft-versus-Host Disease (i.e. the role of B cells) is already having an impact on therapy. Novel agents such as pentostatin, mycophenolate mofetil, rituximab, extracorporeal photochemotherapy, etc. are improving the outcome of steroid refractory chronic graft-versus-Host Disease.
-
Novel strategies for steroid-refractory acute graft-versus-Host Disease.
Current Opinion in Hematology, 2005Co-Authors: Javier Bolaños-meade, Georgia Boyce VogelsangAbstract:Purpose of review Graft-versus-Host Disease is one of the commonest complications of allogeneic bone marrow or peripheral blood stem cell transplantation. This review will cover advances in the pathophysiology of graft-versus-Host Disease and new agents under investigation for the treatment of this disorder. Patients developing graft-versus-Host Disease who fail to respond to steroids have a poor prognosis. In this group of people, morbidity and mortality are very high. Recent findings Novel agents are currently under investigation for the treatment of such devastating disorders. Pentostatin, denileukin diftitox, mycophenolate mofetil, extracorporeal photopheresis, and several monoclonal antibodies have been used, some of them with encouraging results. Summary As supportive care improves and new agents are added to the armamentarium against steroid-refractory acute graft-versus-Host Disease, the prognosis of this entity may start to change. Patients with this complication after transplantation should be enrolled, whenever possible, in clinical trials to find effective therapies.
Jeanne Palmer - One of the best experts on this subject based on the ideXlab platform.
-
overlap subtype of chronic graft versus Host Disease is associated with an adverse prognosis functional impairment and inferior patient reported outcomes a chronic graft versus Host Disease consortium study
Haematologica, 2012Co-Authors: Joseph Pidala, Steven Z. Pavletic, Barry E. Storer, Xiaoyu Chai, Georgia Boyce Vogelsang, Corey Cutler, Madan Jagasia, Daniel J Weisdorf, Paul J Martin, Jeanne PalmerAbstract:Background The National Institutes of Health Consensus Conference proposed the term “overlap” graft- versus -Host Disease to describe the situation when both acute and chronic graft- versus -Host Disease are present. Design and Methods We examined whether the overlap subtype of graft- versus -Host Disease was associated with a different prognosis, functional limitations, or patient-reported outcomes compared to “classic” chronic graft- versus -Host Disease without any acute features. Results Prospective data were collected from 427 patients from nine centers. Patients were classified as having overlap (n=352) or classic chronic (n=75) graft- versus -Host Disease based on reported organ involvement. Overlap cases had a significantly shorter median time from transplantation to cohort enrollment ( P =0.01), were more likely to be incident cases ( P <0.001), and had a lower platelet count at onset of the graft- versus -Host Disease ( P <0.001). Patients with overlap graft- versus -Host Disease had significantly greater functional impairment measured by a 2-minute walk test, higher symptom burden and lower Human Activity Profile scores. Quality of life was similar, except patients with overlap graft- versus -Host Disease had worse social functioning, assessed by the Short Form-36. Multivariable analysis utilizing time-varying covariates demonstrated that the overlap subtype of graft- versus -Host Disease was associated with worse overall survival (HR 2.1, 95% CI 1.1–4.7; P =0.03) and higher non-relapse mortality (HR 2.8, 95% CI 1.2–8.3; P =0.02) than classic chronic graft- versus -Host Disease. Conclusions These findings suggest that the presence of acute features in patients with chronic graft- versus -Host Disease is a marker of adverse prognosis, greater functional impairment, and higher symptom burden.
-
Overlap subtype of chronic graft-versus-Host Disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study
Haematologica, 2011Co-Authors: Joseph Pidala, Steven Z. Pavletic, Barry E. Storer, Xiaoyu Chai, Georgia Boyce Vogelsang, Corey Cutler, Madan Jagasia, Daniel J Weisdorf, Paul Martin, Jeanne PalmerAbstract:Background The National Institutes of Health Consensus Conference proposed the term “overlap” graft- versus -Host Disease to describe the situation when both acute and chronic graft- versus -Host Disease are present. Design and Methods We examined whether the overlap subtype of graft- versus -Host Disease was associated with a different prognosis, functional limitations, or patient-reported outcomes compared to “classic” chronic graft- versus -Host Disease without any acute features. Results Prospective data were collected from 427 patients from nine centers. Patients were classified as having overlap (n=352) or classic chronic (n=75) graft- versus -Host Disease based on reported organ involvement. Overlap cases had a significantly shorter median time from transplantation to cohort enrollment ( P =0.01), were more likely to be incident cases ( P